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Abstract: A series of six 4-(arylmethylidene)-2-phenyl/methyl-5(4H)-oxazo-
lone derivatives were synthesized using a reported method by condensation of 
aldehydes with N-benzoyl/N-acetyl glycine in the presence of zinc oxide as a 
catalyst and acetic anhydride at room temperature in ethanol. Five of the 
compounds are new derivatives. The structures of the compounds were eva-
luated based on 1H-NMR,  13C-NMR, EI-MS and FT-IR spectroscopy and 
elemental analysis. All the compounds were screened for their antibacterial and 
urease inhibition activity. The antibacterial activity was tested by the agar well 
diffusion method using Mueller–Hinton agar medium. Compound 2 showed 
excellent activity against Staphylococcus aureus exhibiting 16 mm (80 %) inhi-
bition and above 24 mm (70 %) against Salmonella typhi. Compound 6 was the 
most active compound against Escherichia coli having 20 mm (80 %) inhi-
bition followed by compound 5 having above 18 mm (70 %) inhibition. Urease 
inhibition  activity of all the compounds was determined by the indophenol 
method. Compounds 3, 6 and 7 showed significant inhibition against Jack bean 
urease. 
Keywords:  aldehyde; antibacterial; urease inhibition activities; oxazolones; 
synthesis; zinc oxide. 
INTRODUCTION 
For many decades, increasing resistance against human pathogens that cause 
serious infections is one of the main topics of interest for medicinal chemists. 
During the last century, many medicines were developed against bacterial infec-
tions. However, the available antibacterial drugs could cause undesirable effects 
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and might be toxic. In view of these facts, it is important to explore additional 
drugs that have no adverse effects due to their different mode of action. In recent 
years, there has also been an increased interest in urease inhibiting drugs. Urease 
is a major cause of peptic and gastric ulcer. Compounds having urease inhibitory 
potential play an important role in pharmaceutical companies.1 Activities of ure-
ase (E. C. 3.5.1.5) has been shown to be important virulence determinant in the 
pathogenesis of many clinical conditions, which are detrimental for human and 
animal health. Urease is directly involved in the formation of infection stones and 
contributes to the pathogenesis of urolithiasis, pyelonephritis, ammonia and 
heptic encephalopathy, hepatic coma and urinary catheter encrustation.2,3 For the 
above reasons, a wide range of resistant drugs are important and required to treat 
patients. Mostly nitrogen-, sulfur- and oxygen-containing five- and six-mem-
bered heterocyclic compounds have enormous significance in the field of medi-
cinal chemistry.4 Oxazolones are five-membered heterocyclic compounds con-
taining nitrogen and oxygen as hetero atoms. The C-2 and C-4 positions of oxa-
zolone are responsible for their various biological activities. Oxazolones perform 
an important role in the synthesis of several organic molecules, including amino 
acids,5 amino alcohols, thiamine6 and peptides.7 Certain natural and synthetic 
oxazolones also possess important biological activities, such as anti-inflamma-
tory,8 antimicrobial,9 anticancer,10 anti-HIV,11 anti-angiogenic,12 anticonvul-
sant,13 antitumor, antagonistic, sedative14–16 and cardiotonic activity.17. Oxazo-
lone plays a very vital role in the manufacture of various biologically active 
drugs, such as analgesic, anti-inflammatory, antidepressant, anticancer, antimic-
robial, antidiabetic and anti-obesity compounds.18,19 
In the literature, the syntheses of oxazolone derivatives were achieved by 
condensation of aldehydes with N-benzoyl/N-acetyl glycine in the presence of 
various reagents and catalysts, such as, ZnCl2,20 KF/NaOAc,21 Al2O3–H3BO3,22 
Bi(III) salts23 and Pb(OAc)2.24 Herein, the synthesis of a series of 4-(arylmethyl-
idene)-2-phenyl/methyl-5(4H)-oxazolone derivatives (2–7) using a literature 
method25 by the condensation of an aldehyde with N-benzoyl/N-acetyl glycine in 
the presence of zinc oxide as a catalyst at room temperature in ethanol is reported. 
Compounds 2–6 are new. All the synthesized compounds were tested for their 
urease inhibition activity and antibacterial activity against Escherichia coli, 
Bacillus subtilis, B. cereus, Staphylococcus aureus, Pseudomonas aeruginosa, 
Salmonella typhi and Proteus mirabilis.  
EXPERIMENTAL 
All chemicals were of AR grade. The melting points were measured using Gallen Kemp 
MF-370 apparatus. The IR spectra were recorded on Nicolet Avatar 300 DTGS instrument. 
The 1H- and 13C-NMR spectra were recorded on a Bruker AV-300 instrument operating at 
300 and 75 MHz, respectively, in dimethyl sulfoxide (DMSO) with trimethylsilane (TMS) as 
an internal standard. The EI-MS were recorded on a Finnigan MAT-311 A. CHN analysis was 
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performed on a Carlo Erba Strumentazione-Mod-1106, Italy. Purity of the product was 
determined by using silica gel 60F254 TLC, pre-coated cards (0.2 mm thickness) and visu-
alized under UV light (254 and 366 nm) and by iodine vapors.  
Antibacterial assay 
Antibacterial activity was tested by the agar well diffusion method using Mueller Hinton 
Agar medium for the assay. The microorganisms were activated by inoculating a loopful of 
the strains in the nutrient broth (25 mL) and incubating at room temperature on a rotary 
shaker. Then 0.2 mL of inoculum (inoculum concentration was 108 cells mL-1 as per the 
McFarland standard) was inoculated into the molten Mueller–Hinton agar media and after 
proper homogenization, it was poured into 20 mm×100 mm Petri dishes. For the agar well 
diffusion, a well was made in the seeded plates with the help of a cup-borer (8.5 mm). The 
reference standard and test sample (1 %) 0.1 mL was introduced into the well and all the 
plates were incubated at 37 °C for 24 h. The microbial growth was determined by measuring 
the zone of inhibition (mm) and the mean values are presented. Percentage inhibitions of the 
compounds were determined by comparing the zone of inhibition to that of standard drug 
against each organism. 
Urease inhibition assay 
Reaction mixtures comprising 25 μL of enzyme (jack bean urease) solution and 55 μL of 
buffers containing 100 mM urea were incubated with 5 μL of the test compounds (1 mM con-
centration) at 30 °C for 15 min in 96-well plates. The urease activity was determined by 
measuring ammonia production using the indophenol method as described by Weatherburn.26 
Briefly, 45 μL each of phenol reagent (1 % w/v phenol and 0.005 % w/v sodium nitroprus-
side) and 70 μL of alkali reagent (0.5 % w/v NaOH and 0.1 % (w/v) active chlorine NaOCl) 
were added to each well. The increasing absorbance at 630 nm was measured after 50 min, 
using a microplate reader (Molecular Device, USA). All reactions were performed in triplicate 
in a final volume of 200 μL. The results (change in absorbance per min) were processed using 
Soft Max Pro software (Molecular Device, USA). All the assays were performed at pH 8.2 
(0.01 M K2HPO4·3H2O, 1 mM EDTA and 0.01 M LiCl). The percentage inhibitions were 
calculated from the formula 100–(ODtestwell/ODcontrol)×100. Thiourea was used as the standard 
inhibitor of urease. 
Synthesis of N-benzoylglycine (1a) 
Glycine (10 g, 133 mmol) was dissolved in 10 % NaOH solution (100 mL) and benzoyl 
chloride (21.6 ml, 186 mmol) was added in portions to this solution in 500mL conical flask. 
After each addition, the flask was stoppered and shaken vigorously until all the acid chloride 
had reacted. The solution was cooled by adding few grams of crushed ice and concentrated 
hydrochloric acid (pH 2–3) was added. The so-formed precipitates were filtered and washed 
several times with cold distilled water, dried, and recrystallized from hot water. The required 
compound was obtained as a crystalline white solid. 
Synthesis of N-acetylglycine (1b) 
Glycine (10 g, 133 mmol) and water (30 mL) in a 500 mL conical flask was vigorously 
stirred until the solid glycine had completely dissolved. Acetic anhydride (25 mL, 266 mmol) 
was added in portions and stirred vigorously for 20 min. The exothermic reaction produced 
solid N-acetylglycine, which showed the end-point of the reaction. The reaction mixture was 
then placed in refrigerator overnight for the complete formation of the product. The solid was 
filtered, washed with ice-cooled water and recrystallized from hot water. 
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Synthesis of the 4-(arylmethylidene)-2-phenyl/methyl-5-(4H)-oxazolones derivatives (2–7) 
A mixture of the required aldehyde (1 mmol), N-benzoylglycine/N-acetylglycine (1 mmol), 
acetic anhydride (3 mmol), ZnO as a catalyst (0.05 mmol) and 15 mL ethanol was stirred at 
room temperature, 25 °C (Scheme 1). After a certain period, the syrupy reaction mixture was 
solidified and the reaction was completed (Table I). After the final product had been obtained, 
20 mL more of cold ethanol was added. The solid was filtered off, dried and washed with hot 
water before recrystallization of the product. 
 
Scheme 1. Synthesis of oxazolones 2–7; a) acetic anhydride or benzoyl chloride, 10 % NaOH, 
H2O; b) ZnO, acetic anhydride, C2H5OH, reflux under stirring at r.t. 
TABLE I. Synthesis of oxazolone derivatives (2–7) with their physical parameters 
Compound   R1 R 2  Yield
% 
Molecular weight
g mol-1 
Reaction time 
min 
M.p. 
°C 
2 
 
89 328  10  227 
3 
 H3CO
92 305  15  118 
4    80 266  12  160 
5    70 360  19  166 
6 
 
82 423  15  149 
7 
 
70 
 
293 10  197 
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RESULTS AND DISCUSSION 
Chemistry 
Oxazolone derivatives were synthesized by condensation of substituted aro-
matic aldehydes with N-benzoyl/N-acetyl glycine using zinc oxide as a catalyst in 
ethanol at room temperature. All the synthesized compounds were characterized 
using different spectroscopic techniques. The IR spectrum of compound 3, as 
typical, showed characteristic band of carbonyl group at 1781 and C=N at 1652 
cm–1. Also, typical 1H-NMR spectrum showed characteristic pattern of peaks. 
The methyl protons appeared in the region of 3.84 ppm, whereas the aromatic 
protons appeared at 6.89–8.12 ppm. The electron ionization mass spectrometric 
fragmentation patterns of the compounds were the same. 
The complete analytic and spectral data of the obtained products are given in 
the Supplementary material to this paper. 
Antibacterial activity 
All the compounds (2–7) were tested for their antibacterial activity against 
Escherichia coli, Bacillus subtilis, B. cereus, Staphylococcus aureus, Pseudomo-
nas aeruginosa, Salmonella typhi and Proteus mirabilis. The results were com-
pared with those of the standard 0.3 % gentamycin. The antibacterial activity of 
compounds 2–7 are shown in Fig 1. The bacterial zones of inhibition values are 
summarized in Table II. Compounds 5 and 6 showed excellent activities against 
E. coli, which is very difficult to treat with traditionally used antibiotics. The 
most active compound against E. coli was compound 6 having 20 mm inhibition 
zone (80 % inhibition), followed by compound 5 having above 18 mm inhibition 
zone (70 %). Thus, compounds 5 and 6 would be the better choice for the 
treatment of infections caused by E. coli than the derivatives 1–4 or 7. All the 
screened compounds showed low to moderate activities against B. cereus, except 
 
Fig. 1. Antibacterial activity of compounds 2–7. 
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compound 4 that showed 50 % inhibition. S. aureus is responsible for various 
throat infections and cholic diseases. Therefore, compound 2 would be the best 
choice to treat infections caused by S. aureus as it had a 16 mm inhibition zone 
(80 %). None of the compounds showed inhibition against P. aeruginosa except 
compound 2 that had less than 30 % inhibition. S. typhi, responsible for typhoid, 
could be inhibited by compound 2, showing an inhibition zone of 24 mm (70 %). 
Compound  4 also showed 50 % inhibition followed by compounds 5–7.  B. 
subtilis was only inhibited by compound 6, which showed an inhibition zone of 
15 mm (75 %). Compound 6 also showed ≈20 mm inhibition zone (50 %) against 
P. mirabilis, followed by compounds 4, 5 and 7. 
TABLE II. Antibacterial activity (concentration used: 1 % of each compound); zone of inhi-
bition was measured in mm; SD – standard drug, 0.3 % gentamycin 
Bacterium 
Compound 
SD 
2 3 4 5  6  7 
E. coli  10 00 12 18  20  00 25 
B. cereus  00 00 15 10  12  09 30 
S. aureus  16 05 00 00  12  00 20 
P. aeruginosa  10 00 00 05  00  00 35 
S typhi  24 08 16 12  10  00 34 
B. subtilis  00 00 00 00  15  00 20 
P. mirabilis  12 00 10 15  20  10 39 
Compounds 5 and 6 proved themselves to be very effective antibacterial 
agents. Compound 5 showed inhibition against four and compound 6 showed 
inhibitions against six different bacterial strains. The C-2 and C-4 positions of the 
oxazolones are responsible for their crucial biological activities (Fig. 2). A phe-
nyl group instead of a methyl group at C-2 plays a vital role in the enhancement 
of the activities, as shown by compounds 5 and 6. Compared to compound 5, 
compound 6 showed a greater tendency of inhibition against different bacterial 
strains due to the phenyl group at C-2. Electron withdrawing substituents at C-4 
position are also a good choice for the enhancement of the activities. 
Fig. 2. Structure of oxazolones. 
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Urease inhibition activity 
All the synthesized compounds  were screened for their urease inhibition 
activity. Compounds 3,  6 and 7 showed strong inhibition against jack bean 
urease, having IC50 values near to the standard inhibitor thiourea as determined 
by the indophenol method. The results are listed in Table III. 
TABLE III. Urease inhibition activity of compounds 2–7; Standard IC50 = 21.4 µM 
Compound  Urease inhibition, %  IC50 / µM 
2  21 Not  determined 
3  85.2 62 
4  44 NA 
5  49 NA 
6  82.5 65.3 
7  73.2 58 
CONCLUSION 
Based on the biological activities of the synthesized oxazolone derivatives, it 
could be concluded that they are therapeutic antibacterial agents and urease inhi-
bitors. 
SUPPLEMENTARY MATERIAL 
Analytic and spectral data for the synthesized compounds are available electronically 
from http://www.shd.org.rs/JSCS/, or from the corresponding author on request. 
Acknowledgement. All the authors wish to thank the Pharmaceutical Research Center, 
PCSIR Laboratories Complex, Karachi, Pakistan, for financial and technical support for this 
research. 
ИЗВОД 
СИНТЕЗА, СПEКТРАЛНА КАРАКТЕРИЗАЦИЈА И ФАРМАКОЛОШКА ИСПИТИВАЊА 
ДЕРИВАТА ОКСАЗОЛОНА 
GHULAM FAREED1,2, NIGHAT AFZA1, MUHAMMAD ALI VERSIANI2, NAZIA FAREED2, 
UZMA RASHEED MUGHAL3, MAHBOOB ALI KALHORO1, LUBNA IQBAL1 и MEHREEN LATEEF1 
1Pharmaceutical Research Center, PCSIR Laboratories Complex Karachi, Shahrah-e-Dr. Salim-uz-Zaman 
Siddiqui Karachi-75280, Sindh, Pakistan, 2Department of Chemistry, Federal Urdu University of Arts, 
Science and Technology, Ghulshan-e-Iqbal, Karachi-75300, Sindh, Pakistan и 3HEJ Research Institute of 
Chemistry, ICCBS, University of Karachi, Karachi-75280, Pakistan 
Синтетисана  је  серија  деривата 4-(арилметилиден)-2-фенил/метил-5(4H)-оксазо-
лона (2–7) од којих су деривати 2–6 синтетисани први пут. Једињења су синтетисана 
кондензацијом  алдехида  и  N-бензоил/N-ацетил-глицина  у  присуству  цинк-оксида  као 
катализатора и анхидрида сирћетне киселине, на собној температури у етанолу као рас-
тварачу. Структура деривата одређена је спектралном (1H-NMR, 13C-NMR, EI-MS и FT- 
-IR) и елементалном анализом. Свим једињењима одређена је антибактеријска актив-
ност и инхибиторна активност према уреази. Антибактеријска активност је тестирана 
према методи дифузије у агару помоћу Mueller–Hinton агар медијума. Једињење 2 пока-
зује одличну активност према Staphylococcus aureus ≈16 mm (80 %) инхибиције и преко 
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24 mm (70 %) према Salmonella typhi. Према Escherichia coli најактивније је једињење 6 са 
20 mm (80 %) инхибиције,  а  затим  једињење  5  са  преко 18 mm (70 %) инхибиције. 
Инхибиторна активност према уреази за сва једињења одређена је индофенолном мето-
дом. Једињења 3, 6 и 7 показују значајну активност према уреази пасуља сорте Jack. 
(Примљено 17. септембра, ревидирано 21. новембра 2012) 
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